Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (481-490 of 575) with videos related to

Pageof 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trialMark A Socinski, Thomas E Stinchcombe, Dominic T Moore, et al.
Cancer Treatment and Research Communications|March 11, 2019
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinibJared Weiss, Brian Kavanagh, Allison Deal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2017
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)Maria Q Baggstrom, Mark A Socinski, Xiaofei F Wang, et al.
JTO Clinical and Research Reports|June 20, 2022
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL TrialJeffrey M Clarke, Lin Gu, Xiaofei F Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538Jeffrey Bogart, Xiaofei Wang, Gregory Masters, et al.
Genome Biology and Evolution|July 22, 2025
Testing for the Genomic Footprint of Conflict Between Life Stages in an Angiosperm and Moss SpeciesMeng Yuan, Leslie M Kollar, Bianca M Sacchi, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
Psycho-Oncology|December 15, 2025
LiveWell: Pilot Feasibility Trial of an Adapted Dialectical Behavioral Therapy Skills Training Protocol in Patients With Metastatic Non-Small Cell Lung CancerKelly A Hyland, Andrada D Neacsiu, Hannah M Fisher, et al.
Journal of the National Cancer Institute|May 20, 2026
Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901)Melisa L Wong, Minji K Lee, Oudom Kour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trialPasi A Jänne, Xiaofei Wang, Mark A Socinski, et al.
Pageof 58

Showing results (481-490 of 575) with videos related to

Sort By:
Pageof 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trialMark A Socinski, Thomas E Stinchcombe, Dominic T Moore, et al.
Cancer Treatment and Research Communications|March 11, 2019
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinibJared Weiss, Brian Kavanagh, Allison Deal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2017
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance)Maria Q Baggstrom, Mark A Socinski, Xiaofei F Wang, et al.
JTO Clinical and Research Reports|June 20, 2022
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL TrialJeffrey M Clarke, Lin Gu, Xiaofei F Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2023
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538Jeffrey Bogart, Xiaofei Wang, Gregory Masters, et al.
Genome Biology and Evolution|July 22, 2025
Testing for the Genomic Footprint of Conflict Between Life Stages in an Angiosperm and Moss SpeciesMeng Yuan, Leslie M Kollar, Bianca M Sacchi, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
Psycho-Oncology|December 15, 2025
LiveWell: Pilot Feasibility Trial of an Adapted Dialectical Behavioral Therapy Skills Training Protocol in Patients With Metastatic Non-Small Cell Lung CancerKelly A Hyland, Andrada D Neacsiu, Hannah M Fisher, et al.
Journal of the National Cancer Institute|May 20, 2026
Pembrolizumab with or without chemotherapy among older adults with advanced lung adenocarcinoma: a national, nonrandomized open-label phase II trial (Alliance A171901)Melisa L Wong, Minji K Lee, Oudom Kour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trialPasi A Jänne, Xiaofei Wang, Mark A Socinski, et al.
Pageof 58